Analysis of the efficacy and factors influencing the response of secondary hyperparathyroidism patients on hemodialysis to cinacalcet;Análisis de la eficacia y de los factores que influyen en la respuesta del hiperparatiroidismo secundario de pacientes en hemodiálisis a cinacalcet

Nefrologia

Volumn 30, Issue 4, 2010, Pages 443-451

  Segura Torres, P ^a   Borrego Utiel, F J ^a   Sanchez Perales M C ^a   Garcia Cortes M J ^a   Biechy Baldan M M ^a   Perez Banasco V ^a  

^a Servicio de Nefrologia   (Spain)

Author keywords

Cinacalcet; Efficiency; Hemodialysis; Secondary hyperparathyroidism; Sevelamer

Indexed keywords

CINACALCET; NAPHTHALENE DERIVATIVE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; NAPHTHALENES; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 77956008128     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2010.May.10451     Document Type: Article

References (20)

1. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephro 2005;15(3):800-7
2. Messa P, Macário F, Yaqoob M, Bouman K, Braun J, Von Albertini B, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3(1):36-45
3. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67(2):760-71
4. Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinsky DA; TARGET Investigators. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008;23(7):238-8
5. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201
6. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009;76(Suppl 113):S1-129.
7. Arenas MD, Álvarez-Ude F, Gil MT, Moledous A, Malek T, Núñez C, et al. Implementation of «K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease» after the ntroduction of cinacalcet in a population of patients on chronic hae-modialysis. Nephrol Dial Transplant 2007;22:1539-44
8. Malluche HH, Monier-Faugere MC, Wang G, Frazã O JM, Charytan C, Coburn JW, et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 2008;69(4):269-78
9. Shigematsu T, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S; KRN1393 Study Group. Long-term cinacalcet HCl treatment mproved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol 2009;29(3):230-6
10. Ureña P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, et al. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinica practice-the ECHO observational study. Nephrol Dial Transplant 2009;24:2852-9
11. Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008;3(6):1718-25
12. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients Kidney Int 2002;62;245-52
13. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68(4):1815-24
14. Barreto DV, Barreto FC, De Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, et al. Phosphate binder impact on bone remodeling and coronary calcification-results from the BRIC study. Nephron Clin Pract 2008;110:c273-83
15. Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, et al. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20(7):1270-7
16. Lopez I, Mendoza FJ, Aguilera-Tejero E, Pérez J, Guerrero F, Martín D, et al. The effect of calcitriol, paricalcitol and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008;73:300-7
17. Tsuruta Y, Ohbayashi T, Fujii M, Myochin H, Mizutani R, Narita M, et al. Change in coronary artery calcification score due to cinacalcet hydrochloride administration. Ther Apher Dial 2008;11(Supp 1):S34-37
18. Aladrén Regidor MJ. Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients. Clin Nephrol 2009;71(2):207-12
19. Kalantar-Zadeh K, Kovesdy CP. Is it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet story. Am J Kidney Dis 2009;53(2):183-8
20. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70(4):771-80